M2 macrophage infusion ameliorates diabetic glomerulopathy via the JAK2/STAT3 pathway in db/db mice

To explore the therapeutic effects of M2 macrophages in diabetic nephropathy (DN) and their mechanism. We infused M2 macrophages stimulated with IL-4 into 10-week-old db/db mice once a week for 4 weeks through the tail vein as M2 group. Then we investigated the role of M2 macrophages in alleviating...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Renal failure 2024-12, Vol.46 (2), p.2378210
Hauptverfasser:	Gu, Yulin, Yu, Songyan, Gu, Weijun, Li, Bing, Xue, Jing, Liu, Jiejie, Zhang, Qi, Yin, Yaqi, Zhang, Haixia, Guo, Qinghua, Yuan, Mingxia, Lyu, Zhaohui, Mu, Yiming, Cheng, Yu
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Basic Sciences Investigations Cell injury Chemokine CCL2 - metabolism Diabetes Diabetes mellitus Diabetic complication Diabetic Nephropathies - metabolism diabetic nephropathy Disease Models, Animal Glomerulus Homeostasis inflammation Interleukin-1beta - metabolism JAK2/STAT3 pathway Janus kinase Janus kinase 2 Janus Kinase 2 - metabolism Kidney Glomerulus - metabolism Kidney Glomerulus - pathology Kidneys M2 macrophages Macrophages Macrophages - metabolism Male Mesangial cells Mesangial Cells - metabolism Mice Mice, Inbred C57BL Monocyte chemoattractant protein 1 Nephropathy Signal Transduction Stat3 protein STAT3 Transcription Factor - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To explore the therapeutic effects of M2 macrophages in diabetic nephropathy (DN) and their mechanism. We infused M2 macrophages stimulated with IL-4 into 10-week-old db/db mice once a week for 4 weeks through the tail vein as M2 group. Then we investigated the role of M2 macrophages in alleviating the infammation of DN and explored the mechanism. M2 macrophages hindered the progression of DN, reduced the levels of IL-1β (DN group was 34%, M2 group was 13%,
ISSN:	0886-022X 1525-6049 1525-6049
DOI:	10.1080/0886022X.2024.2378210